US FDA to discuss advances for post-market device surveillance studies at March workshop
This article was originally published in SRA
The US Food and Drug Administration is to hold a public workshop on 7 March that explores how to advance the design and methodologies for medical device surveillance studies in the post-market setting1.
You may also be interested in...
Now that the European Medicines Agency has finalized its formal safety review procedure into Xeljanz, Pfizer is telling health care professionals what precautions they must take when prescribing the drug.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.